Modest Activity of Pomalidomide in Patients with Myelofibrosis and Significant Anemia

We evaluated single agent pomalidomide for myelofibrosis-associated anemia. First, 21 patients received pomalidomide 3.0mg/day on 21-day-on/7-day-off schedule. Due to poor tolerance the study was quickly suspended. Second, 29 patients received pomalidomide 0.5mg/day continuously. Three patients (10%...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Leuk Res
Autori principali: Daver, Naval, Shastri, Aditi, Kadia, Tapan, Quintas-Cardama, Alfonso, Jabbour, Elias, Konopleva, Marina, O’Brien, Susan, Pierce, Sherry, Zhou, Lingsha, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4232180/
https://ncbi.nlm.nih.gov/pubmed/23890523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.07.007
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi